All Mark T. Gladwin articles
-
NewsFirst-in-human clinical trial shows promising results for new Lassa fever vaccine
Researchers have reported encouraging results from an early clinical trial that tested a new dual vaccine against Lassa fever and rabies. The study found that the vaccine was safe and induced immune responses against both viruses. There are currently no vaccines against Lassa fever on the market.
-
NewsEarly-stage clinical trial demonstrates promise of intranasal influenza vaccine in generating broad immunity
Researchers report encouraging results from an early phase clinical trial that found an experimental intranasal vaccine triggered a broad immune response against multiple strains of H5N1 ’bird flu’, highlighting the potential of mucosal immunization strategies.
-
NewsNew monoclonal antibody shows promise for preventing malaria infections
A new early-stage clinical trial has found that a novel monoclonal antibody provided dose-dependent full protection against the malaria parasite with minimal side effects.
-
NewsNew vaccine shows promise against typhoid and invasive salmonella in first human trial
Researchers have completed a successful Phase 1 clinical trial of a novel vaccine designed to protect against both typhoid fever and invasive non-typhoidal Salmonella–two major causes of illness and death among children in sub-Saharan Africa.
-
NewsBacterial protein therapy shows promise as first-ever antidote for carbon monoxide poisoning
Researchers have engineered a new molecule that appears promising as an effective antidote for carbon monoxide poisoning with fewer side effects than other molecules currently being tested.
-
NewsMeningococcal vaccine found to be safe and effective for infants in sub-Saharan Africa
A new global health study found a vaccine that protects against five strains of meningitis prevalent in sub-Saharan Africa is safe and effective for use in young children beginning at 9 months of age.
-
NewsVaccine development program aims to prevent sepsis in newborns
Researchers have been awarded $3.96 million to develop a maternal vaccine that prevents sepsis caused by Klebsiella pneumoniae in newborns and infants.
-
NewsResearchers identify new genetic risk factors for persistent HPV infections
A new finding suggests that certain women may have a genetic susceptibility for persistent or frequent HPV infections, potentially raising their risk of getting cervical cancer from a high-risk HPV infection.
-
NewsSingle dose typhoid conjugate vaccine (TCV) provides lasting efficacy in children
A single dose of the typhoid conjugate vaccine, Typbar TCV®, provides lasting efficacy in preventing typhoid fever in children ages 9 months to 12 years old, according to a new study.